Clinical studies have demonstrated that immune checkpoint inhibitors targeting this pathway (e.g., Cosibelimab) can restore the antitumor activity of T cells by blocking the interaction between PD-L1 and PD-1, leading to significant survival benefits in patients with cSCC (48). Here, CD274 is linked to skin squamous cell carcinoma.